GLPG-1690
GLPG-1690 (Ziritaxestat, GLPG1690) is a first-in-class, potent, competitive autotaxin inhibitor with Ki/IC50 of 15 nM/131 nM; inhibits ATX-induced LPA 18:2 production in mouse, rat, and healthy donor plasma with IC50 of 418 nM, 542 nM, and 242 nM, respectively; shows no CYP3A4 TDI and decreased hERG inhibitory activity (IC50=15 uM), and good pharmacokinetic profile for treatment idiopathic pulmonary fibrosis.Fibrosis, Phase 2 Clinical.
Product Specifications
CAS Number
1628260-79-6
Product Name Alternative
Ziritaxestat | GLPG 1690 | GLPG1690
Purity
>98% (HPLC)
Solubility
DMSO: Soluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
Smiles
CCC (N=C1N2C=C (C=C1C) N3CCN (CC3) CC (N4CC (C4) O) =O) =C2N (C) C5=NC (C6=CC=C (C=C6) F) =C (S5) C#N
Molecular Formula
C30H33FN8O2S
Molecular Weight
588.71
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
